New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0

World Journal of Gastroenterology

Volumn 11, Issue 4, 2005, Pages 469-475

  Mukaide, Motokazu ^a   Tanaka, Yasuhito ^b   Kakuda, Hirokazu ^a   Fujiwara, Kei ^b   Kurbanov, Fuat ^b   Orito, Eturo ^b   Yoshioka, Kentaro ^c   Fujise, Kiyotaka ^d   Harada, Shoji ^a   Kozaki, Takazumi ^a   Takemura, Kazuo ^a   Hikiji, Kazumasa ^a   Mizokami, Masashi ^a  

^a SRL INC   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Genotype; HCV Guideline test; Hepatitis C Virus; Viral load

Indexed keywords

BIOTIN;

ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DECISION MAKING; DIAGNOSTIC KIT; DIAGNOSTIC PROCEDURE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MOLECULAR EVOLUTION; MOLECULAR PROBE; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGONUCLEOTIDE PROBE; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREDICTION; PROCESS DEVELOPMENT; SENSITIVITY AND SPECIFICITY; SEROLOGY; SEROTYPE; TREATMENT OUTCOME; VIRUS LOAD;

EID: 19944430999     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i4.469     Document Type: Article

References (34)

1. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A non-B hepatitis. N Engl J Med 1989; 321: 1494-1500
2. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16
3. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shih JW, Gojobori T, Alter HJ. Inaugural Article: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A 2002; 99: 15584-15589
4. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, Gojobori T, Maertens G, Mizokami M, Nainan O, Netesov S, Nishioka K, Shin i T, Simmonds P, Smith D, Stuyver L, Weiner A. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998; 143 2493-2503
5. Orito E, Mizokami M, Nakano T, Terashima H, Nojiri O, Sakakibara K, Mizuno M, Ogino M, Nakamura M, Matsumoto Y. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C. J Med Virol 1994; 44: 410-414
6. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-299
7. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Tanaka N, Arakawa Y, Omata M. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997; 113: 558-566
8. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36(5 Suppl 1): S121-127
9. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-609
10. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 9: 228-337
11. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-1569
12. Seeff LB. Natural histry of chronic hepatitis C. Hepatology 2002; 36: 35-46
13. Ikeda K, Kobayashi M, Someya T, Saitoh S, Tsubota A, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H. Influence of hepatitis C virus subtype on hepatocellular carcinogenesis: a multi-variate analysis of a retrospective cohort of 593 patients with cirrhosis. Intervirology 2002; 45: 71-78
14. Holland J, Bastian I, Ratcliff RM, Beers MY, Hahesy P, Harley H, Shaw DR, Higgins GD. Hepatitis C genotyping by direct sequencing of the product from the Roche AMPLICOR test: methodology and application to a South Australian population. Pathology 1998; 30 192-195
15. Germer JJ, Rys PN, Thorvilson JN, Persing DH. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999; 37: 2625-2630
16. Ansaldi F, Torre F, Bruzzone BM, Picciotto A, Crovari P, Icardi G. Evaluation of a new hepatitis C virus sequencing assay as a routine method for genotyping. J Med Virol 2001; 63: 17-21
17. Zheng X, Pang M, Chan A, Roberto A, Warner D, Yen-Lieberman B. Direct comparison of hepatitis C virus genotypes tested by INNO-LiPA HCV II and TRUGENE HCV genotyping methods. J Clin Virol 2003; 28: 214-216
18. Okamoto H, Sugiyama Y, Okada S, Kurai K, Aka-hane Y, Sugai Y, Tanaka K, Sato K, Tsuda F, Miyakawa M. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673-679
19. Ohno T, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, Mukaide M, Williams R, Lau JY. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35: 201-207
20. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, Ohta Y, Hattori N, Kohara M. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347-1353
21. Mizokami M, Gojobori T, Lau JY. Molecular evolutionary virology: its application to hepatitis C virus. Gastroenterology 1994: 107: 1181-1182
22. Gojobori T, Ishii K, Nei M. Estimation of the average number of nucleotide substitutions when the rate of substitution varies with nucleotide. J Mol Evol 1982; 28: 414-423
23. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987; 4: 406-425
24. Germer JJ, Zein NN. Advances in the molecular diagnosis of hepatitis C and their clinical implications. Mayo Clin Proc 2001; 76: 911-920
25. Mazzeo C, Azzaroli F, Giovanelli S, Dormi A, Festi D, Colecchia A, Miracolo A, Natale P, Nigro G, Alberti A, Roda E, Mazzella G. Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. Gut 2003; 52: 1030-1034
26. Kleter GE, van Doorn LJ, Stuyver L, Maertens G, Brouwer JT, Schalm SW, Heijtink RA, Quint WG. Rapid genotyping of hepatitis C virus RNA-isolates obtained from patients residing in western Europe. J Med Virol 1995; 47: 35-42
27. Furione M, Simoncini L, Gatti M, Baldanti F, Grazia Revello M, Gerna G. HCV genotyping by three methods: analysis of discordant results based on sequencing. J Clin Virol 1999; 13 121-130
28. Halfon P, Trimoulet P, Bourliere M, Khiri H, de Ledinghen V, Couzigou P, Feryn JM, Alcaraz P, Renou C, Fleury HJ, Ouzan D. Hepatitis C virus genotyping based on 5′ noncoding sequence analysis (Trugene). J Clin Microbiol 2001; 39: 1771-1773
29. Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, Bach N, Smith C, Herrera J, Tobias H, Conrad A, Schmid P, McHutchison JG. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000; 7: 196-202
30. Simmonds P, Mellor J, Craxi A, Sanchez-Tapias JM, Alberti A, Prieto J, Colombo M, Rumi MG, Lo Iacano O, Ampurdances-Mingall S, Forns-Bernhardt X, Chemello L, Civeira MP, Frost C, Dusheiko G. Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. J Hepatol 1996; 24: 517-524
31. Fattovich G, Ribero ML, Pantalena M, Diodati G, Almasio P, Nevens F, Tremolada F, Degos F, Rai J, Solinas A, Mura D, Tocco A, Zagni I, Fabris F, Lomonaco L, Noventa F, Realdi G, Schalm SW, Tagger A. Eurohep Study Group on Viral Hepatitis. Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. J Viral Hepat 2001; 8: 206-216
32. Mellor J, Walsh EA, Prescott LE, Jarvis LM, Davidson F, Yap PL, Simmonds P. Survey of type 6 group variants of hepatitis C virus in Southeast Asia by using a core-based genotyping assay. J Clin Microbiol 1996; 34: 417-423
33. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
34. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982